Skip to main content
Future Journal of Pharmaceutical Sciences

Table 5. Assay result of marketed formulation

From: A new RP–HPLC method for simultaneous quantification of perindopril erbumine, indapamide, and amlodipine besylate in bulk and pharmaceutical dosage form

Formulation

Name drug

Conc.

(μg/ml)

Amount found ± SD (n=3)

% Amount of drug found ± SD (n=3)

Triplixam

Perindopril erbumine

4.0

3.96 ± 0.03

99.03 ± 0.80

Indapamide

1.25

1.26 ± 0.01

100.64 ± 0.74

Amlodipine besylate

5.0

4.97 ± 0.04

99.35 ± 0.78

  1. Each tablet contain: Perindopril erbumine – 4.0 mg, Indapamide – 1.25 mg and Amlodipine besylate – 5.0 mg
Back to article page